̽��ֱ�� of Cambridge - implant

Cambridge researchers developing brain implants for treating Parkinson’s disease

sc604 — Thu, 23 Jan 2025 10:33:21 +0000

As part of a £69 million funding programme supported by the Advanced Research + Invention Agency (ARIA), Professor George Malliaras from Cambridge’s Department of Engineering will co-lead a project that uses small clusters of brain cells called midbrain organoids to develop a new type of brain implant, which will be tested in animal models of Parkinson’s disease.

̽��ֱ��project led by Malliaras and Professor Roger Barker from the Department of Clinical Neurosciences, which involves colleagues from the ̽��ֱ�� of Oxford, the ̽��ֱ�� of Lund and BIOS Health, is one of 18 projects funded by ARIA as part of its Precision Neurotechnologies programme, which is supporting research teams across academia, non-profit R&D organisations, and startups dedicated to advancing brain-computer interface technologies.

̽��ֱ��programme will direct £69 million over four years to unlock new methods for interfacing with the human brain at the neural circuit level, to treat many of the most complex neurological and neuropsychiatric disorders, from Alzheimer’s to epilepsy to depression.

By addressing bottlenecks in funding and the lack of precision offered by current approaches, the outputs of this programme will pave the way for addressing a much broader range of conditions than ever before, significantly reducing the social and economic impact of brain disorders across the UK.

Parkinson’s disease occurs when the brain cells that make dopamine (a chemical that helps control movement) die off, causing movement problems and other symptoms. Current treatments, like dopamine-based drugs, work well early on, but can cause serious side effects over time.

In the UK, 130,000 people have Parkinson’s disease, and it costs affected families about £16,000 per year on average – more than £2 billion in the UK annually. As more people age, the number of cases will grow, and new treatments are urgently needed.

One idea is to replace the lost dopamine cells by transplanting new ones into the brain. But these cells need to connect properly to the brain’s network to fix the problem, and current methods don’t fully achieve that.

In the ARIA-funded project, Malliaras and his colleagues are working on a new approach using small clusters of brain cells called midbrain organoids. These will be placed in the right part of the brain in an animal model of Parkinson’s disease. They’ll also use advanced materials and electrical stimulation to help the new cells connect and rebuild the damaged pathways.

“Our ultimate goal is to create precise brain therapies that can restore normal brain function in people with Parkinson’s,” said Malliaras.

“To date, there’s been little serious investment into methodologies that interface precisely with the human brain, beyond ‘brute force’ approaches or highly invasive implants,” said ARIA Programme Director Jacques Carolan. “We’re showing that it’s possible to develop elegant means of understanding, identifying, and treating many of the most complex and devastating brain disorders. Ultimately, this could deliver transformative impact for people with lived experiences of brain disorders.”

Other teams funded by the programme include one at Imperial College London who is developing an entirely new class of biohybridised technology focused on engineering transplanted neurons with bioelectric components. A Glasgow-led team will build advanced neural robots for closed-loop neuromodulation, specifically targeting epilepsy treatment, while London-based Navira will develop a technology for delivering gene therapies across the blood-brain barrier, a crucial step towards developing safer and more effective treatments.

Adapted from an ARIA media release.

Cambridge researchers are developing implants that could help repair the brain pathways damaged by Parkinson’s disease.

Our ultimate goal is to create precise brain therapies that can restore normal brain function in people with Parkinson’s

George Malliaras

Science Photo Library via Getty Images

Substantia nigra in the human brain, illustration

̽��ֱ��text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright © ̽��ֱ�� of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

Soft, stretchy ‘jelly batteries’ inspired by electric eels

sc604 — Wed, 17 Jul 2024 18:00:00 +0000

̽��ֱ��researchers, from the ̽��ֱ�� of Cambridge, took their inspiration from electric eels, which stun their prey with modified muscle cells called electrocytes.

Like electrocytes, the jelly-like materials developed by the Cambridge researchers have a layered structure, like sticky Lego, that makes them capable of delivering an electric current.

̽��ֱ��self-healing jelly batteries can stretch to over ten times their original length without affecting their conductivity – the first time that such stretchability and conductivity has been combined in a single material. ̽��ֱ��results are reported in the journal Science Advances.

̽��ֱ��jelly batteries are made from hydrogels: 3D networks of polymers that contain over 60% water. ̽��ֱ��polymers are held together by reversible on/off interactions that control the jelly’s mechanical properties.

̽��ֱ��ability to precisely control mechanical properties and mimic the characteristics of human tissue makes hydrogels ideal candidates for soft robotics and bioelectronics; however, they need to be both conductive and stretchy for such applications.

“It’s difficult to design a material that is both highly stretchable and highly conductive, since those two properties are normally at odds with one another,” said first author Stephen O’Neill, from Cambridge’s Yusuf Hamied Department of Chemistry. “Typically, conductivity decreases when a material is stretched.”

“Normally, hydrogels are made of polymers that have a neutral charge, but if we charge them, they can become conductive,” said co-author Dr Jade McCune, also from the Department of Chemistry. “And by changing the salt component of each gel, we can make them sticky and squish them together in multiple layers, so we can build up a larger energy potential.”

Conventional electronics use rigid metallic materials with electrons as charge carriers, while the jelly batteries use ions to carry charge, like electric eels.

̽��ֱ��hydrogels stick strongly to each other because of reversible bonds that can form between the different layers, using barrel-shaped molecules called cucurbiturils that are like molecular handcuffs. ̽��ֱ��strong adhesion between layers provided by the molecular handcuffs allows for the jelly batteries to be stretched, without the layers coming apart and crucially, without any loss of conductivity.

̽��ֱ��properties of the jelly batteries make them promising for future use in biomedical implants, since they are soft and mould to human tissue. “We can customise the mechanical properties of the hydrogels so they match human tissue,” said Professor Oren Scherman, Director of the Melville Laboratory for Polymer Synthesis, who led the research in collaboration with Professor George Malliaras from the Department of Engineering. “Since they contain no rigid components such as metal, a hydrogel implant would be much less likely to be rejected by the body or cause the build-up of scar tissue.”

In addition to their softness, the hydrogels are also surprisingly tough. They can withstand being squashed without permanently losing their original shape, and can self-heal when damaged.

̽��ֱ��researchers are planning future experiments to test the hydrogels in living organisms to assess their suitability for a range of medical applications.

̽��ֱ��research was funded by the European Research Council and the Engineering and Physical Sciences Research Council (EPSRC), part of UK Research and Innovation (UKRI). Oren Scherman is a Fellow of Jesus College, Cambridge.

Reference:
Stephen J.K. O’Neill et al. ‘Highly Stretchable Dynamic Hydrogels for Soft Multilayer Electronics.’ Science Advances (2024). DOI: 10.1126/sciadv.adn5142

Researchers have developed soft, stretchable ‘jelly batteries’ that could be used for wearable devices or soft robotics, or even implanted in the brain to deliver drugs or treat conditions such as epilepsy.

Scherman Lab

Jelly batteries

Yes

‘Biohybrid’ device could restore function in paralysed limbs

sc604 — Wed, 22 Mar 2023 17:55:29 +0000

Researchers have developed a new type of neural implant that could restore limb function to amputees and others who have lost the use of their arms or legs.